#Novavax

Carl Zimmer

carlzimmer

Today was a day that vaccine researchers had been hoping for and dreading all year, ever since—back on January 10—scientists started designing coronavirus vaccines. Why? A thread! https://www.nytimes.com/2020/07/17/health/coronavirus-va

Eric Feigl-Ding

DrEricDing

REINFECTION WARNING from the WHO. “We are now getting reports of people getting reinfected with a new variant—from (#B1351)—suggesting people who’ve had prior infection could get infected again.” says

Dr Grace C Roberts 😷

GraceCRoberts

I was up crazy early this morning to get to the hospital on time for my 2nd #Covid #vaccine (21 day booster!)Updates to follow! #COVID19 #Vaccines #Research #Clinicaltrial #clinicalresearch #coronavirus

Carl T. Bergstrom

CT_Bergstrom

No cross-strain protective immunity? Based on what evidence? Even the linked story—which @UW_IHME wrote—says nothing of the kind.I think people still listen to @UW_IHME even after last spring's modeling fiasco.

Tim Bell

timpoliti

The top priority for #ScottyFromMarketing’s federal government in 2021 must be to ensure #coronavirus vaccines are available for everyone ASAP after their approval by the TGA.How’s that looking so far?https://www.health.gov.au/initiativ

Eric Topol

EricTopol

Why 2 proline (P) substitutions will go down in history.Introducing 2P's at the beginning of the central helix (CH) stabilized the spike protein's confirmation upon entering cells.From the Jan 10

Bob Wachter

Bob_Wachter

1/ Covid (@UCSF) Chronicles, Day 317Today was medical grand rounds: brief summary below but worth watching for latest on vaccine distribution in SF, current state of the pandemic, & the

David Benkeser

biosbenk

Interesting thread on single-dose trials. Worth reading to hear from some real public health leaders and Nate Silver.Unfortunately, I don’t see a way forward for new single dose efficacy trials

Mac n’ Chise 🧬🧫🦠

sailorrooscout

Good mRNA vaccine news this morning! Ben Osborn, the UK head of Pfizer, said they do not expect to have to change their vaccine to handle SARS-CoV-2 variants B.1.1.17 and

Zain Rizvi

zainrizvi

NEW: Pfizer CEO Albert Bourla has vociferously denied benefiting from government aid.But his COVID-19 vaccine, like nearly all leading candidates, depend on a critical publicly developed technology.cc: J&J, Novavax, CureVac,

Eric Topol

EricTopol

Big news: The JNJ vaccine results of 44,000 Phase 3 trial, a single dose. Overall 66% efficacy, with the contrast of 72% in US but 57% in South Africa, confirming

Julianna Tatelbaum

CNBCJulianna

The EU's vaccine woes are firmly on display for all to dissect this week. What's gone wrong? A short thread on some of the key issues It's part vaccine

Bloomberg Opinion

bopinion

Historically, vaccine development has been a male-dominated field.But today, the science — which is showing spectacular results — is led by womenhttps://trib.al/Hc6jnXY Women played a major role in developing the

Julian

julianlewis2012

Dr. Kwan, I am wondering if you would reconsider including specific “projection” dates for meeting the vaccine target threshold (i.e. your current 2040 projection).I’d like to respectfully point out a

wombot 👉👀👈

colourmeamused_

This is straight crony capitalism, India effectively diverted capacity that could simply manufacture more AstraZeneca vax for a dubious vaccine from a local firm *that cost the Indian govt more/dose*.https://www.indiatoday.in/coronavirus-ou

rorymcevoy

rorymcevoy

1/4 Covid-19: A positive thread:Now v Peak Ireland14-day incidence: 292 v 1,508 28/28 in EU, now 14/285-day case ave: 835 v c7,0007-day test positivity: 5.7% v 25%Hospital < 900 v

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.